Cellagen Technology LLC
 
작성일 : 16-10-11
[Cellagen Technology LLC] Disease Area, Immunology IV
SD-169 l p38 MAPK inhibitor / Vorinostat (SAHA) l Class I&II HDAC inhibitor / VX-702 l P38 MAPK inhibitor

 

Disease Area, Immunology IV

 

 

Product Name: SD-169 l p38 MAPK inhibitor

클릭하시면 닫힙니다.이미지 저장을 원하시면 마우스 오른쪽클릭후 '다른이름으로 저장'을 하세요

 

SD169 is an indole-5-carboxamide, orally-available, ATP-competitive, a-selective p38 MAPK inhibitor that

targets a wide variety of inflammatory cells, including neutrophils, monocytes, macrophages, B and CD4+ T

cells, and endothelial cells. [1] Through interactions with Schwann cell and TNF activity, SD169 promotes

axonal regeneration in peripheral nerves. [2]

 

SD169 has been shown to reduce myeloma-induced osteolytic bone lesions and restored bone mass by

downregulating osteoclastogenesis and osteoblastogenesis in xenografted primary myeloma-SCID-hu or

myeloma cell line-SCID mouse models. [3] SD169 was also shown downregulates pp38 in myeloma cells in

vitro and in vivo.

 

In the diabetes therapeutic area, SD169 significantly reduces p38 and HSP60 expression in T cells of the

pancreatic beta islets. In studies using hyperglycemic NOD mice, SD169 treatment lowered blood glucose

and improved glucose homeostasis.

 

Details

Chemical Formula:

 

C9H8N2O

CAS No.:

 

1670-87-7

Molecular Weight:

 

160.17

Purity:

 

> 98%

Appearance:

 

White

Chemical Name:

 

1H-indole-5-carboxamide

Solubility:

 

Up to 22 mM in DMSO

Synonyms:

 

SD-169, Sd169

Storage:

 

 

For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution

at -20oC.

 

Reference:

1. Medicherla et al., p38 MAPK inhibition reduces diabetes-induced impairment of wound healing. Diabetes,

   Metab. Syndr. Obes. 2009, 2, 91-100.

2. Myers et al., Inhibition of p38 MAP kinase activity enhances axonal regeneration.  Exp. Neurol. 2003, 184,

    606-614.

3. Yang et al., Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in

   multiple myeloma. Leukemia, 2012, 26, 2114-2123.

4. Medicherla et al., J. Pharmacol. Exp. Ther. 2006, 318(1), 99-107.

  

 

Product Name: Vorinostat (SAHA) l Class I&II HDAC inhibitor

 

클릭하시면 닫힙니다.이미지 저장을 원하시면 마우스 오른쪽클릭후 '다른이름으로 저장'을 하세요

 

Vorinostat (SAHA) is a potent inhibitor of Classes I and II histone deacetylases (HDACs) that works by

chelating Zinc ions found in the active site of HDACs. Vorinostat's inhibition of HDAC activity results in the

accumulation of acetylated histones and acetylated proteins, including transcription factors crucial for the

expression of genes needed to induce cell differentiation.

 

Vorinostat inhibits the proliferation of both normal cells and a wide variety of transformed cells. It induces

death in tumor cells while leaves normal cells alive. Vorinostat inhibits tumor growth in a variety of animal

models1. Marketed under the name Zolinza, Vornostat is a FDA approved medicine for the treatment of

cutaneous T cell lymphoma (CTCL). Vorinostat is now under clinical investigations for several other types of

cancers and for its potential use in eradicating HIV from HIV+ patients2,3.

 

Details

Chemical Formula:

 

C14H20N2O3

CAS No.:

 

149647-78-9

Molecular Weight:

 

264.32

Purity:

 

> 98%

Appearance:

 

White solid

Chemical Name:

 

N-hydroxy-N'-phenyl-octanediamide

Solubility:

 

Up to 50 mM in DMSO

Storage:

 

 

For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution

at -20oC.

 

Reference:

1. Richon VM. Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic

   acid), a novel histone deacetylase inhibitor. Br J Cancer. 2006 Dec95(S1): S2–S6.

2. Contreras X, et al. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol

   Chem. 2009 284 (11): 6782–9.

3.Archin,NM. et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy.

   Nature. 2012 Jul 25;487(7408):482-5.

 

 

Product Name: VX-702 l P38 MAPK inhibitor

 

클릭하시면 닫힙니다.이미지 저장을 원하시면 마우스 오른쪽클릭후 '다른이름으로 저장'을 하세요

 

VX-702 is an orally-available, aminopyridine-based, ATP-competitive inhibitor of p38 MAPK with a Kd of 3.7

nM and 17 nM at 10 uM for p38a and p38b, respectively. In an ex vivo blood assay primed with LPS< VX-702

dose-dependently inhibited the production of IL-6, IL-1b, TNFa at IC50 of 59, 122, and 99 ng/mL, respectively.

VX-702 was found to be equivalent to prednisolone and methotrexate in a mouse collagen-induced arthritis

model.

 

Clinical efficacy models plus transient suppression of inflammation biomarkers suggest that p38 MAPK

inhibition by agents such as VX-702 may not be a viable approach to the treatment of chronic inflammation in

RA.

 

Details

Chemical Formula:

 

C19H12F4N4O2

CAS No.:

 

479543-46-9

Molecular Weight:

 

404.32

Purity:

 

> 98%

Appearance:

 

White

Chemical Name:

 

1-(5-carbamoyl-6-(2,4-difluorophenyl)pyridin-2-yl)-1-(2,6-difluorophenyl)urea

Solubility:

 

Up to 100 mM in DMSO

Synonyms:

 

VX-702. VX702

Storage:

 

 

For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution

at -20oC.

 

Reference:

1. Goldstein et al., Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory

   disorders. J. Med. Chem. 2010, 53, 2345-2353.

2. Ding, C., Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary

   syndrome. Curr. Opin. Invest. Drugs, 2006, 7(11), 1020-1025.

3. Damjanov et al., Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in

    rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis

    Rheum., 2009, 60(5), 1232-1241.

 

 


Ordering informations

   

Catalog No.

Product Name

Size

C7216

SD-169 l p38 MAPK inhibitor

10 mg, 50 mg & 250 mg

C8674

Vorinostat (SAHA) l Class I&II HDAC inhibitor

10 mg, 50 mg & 250 mg

C8970

VX-702 l P38 MAPK inhibitor

5 mg, 25 mg & 100 mg

 

 

▣ 관련 페이지 ; Cellagen Technology